Sarepta Therapeutics (SRPT) Misses Q2 EPS by 7c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Sarepta Therapeutics Announces Second Quarter 2022 Financial Results and Recent Corporate Developments
August 2, 2022 4:06 PM EDT-Â Total revenues, which consist of net product revenues and collaboration revenues, for the second quarter 2022 totaled $233.5 million
-Â Net product revenues for the second quarter 2022 totaled $211.2 million, a 49% increase over the same quarter of prior year
-Â Â Increased full-year total revenue and net product revenue guidance to a range of $905-$920 million and $825-$840 million, respectivelyÂ
CAMBRIDGE, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the... More
